Sugi Predict

Sugi Predict / Compounds / SCHEMBL16035554

SCHEMBL16035554

SCHEMBL16035554

Brc1cc(N2CCOCC2)nc(N2CCOCC2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ KMT2A Q03164 5/20 0.53
▸ MAPT P10636 3/20 0.51
▸ HTT P42858 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ CRHBP P24387 1/20 0.51
▸ CRHR2 Q13324 1/20 0.51
▸ PIK3CB P42338 1/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ NPSR1 Q6W5P4 4/20 0.47
▸ TSHR P16473 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.46
▸ HRH4 Q9H3N8 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16121172 0.87 MAPT (0.61) SMN1; SMN2KMT2AMAPTHTTCYP1A2
SCHEMBL18282242 0.87 KMT2A (0.63) SMN1; SMN2KMT2AMAPTHTTCYP1A2
SCHEMBL2089521 0.87 MAPT (0.53) SMN1; SMN2KMT2AMAPTHTTCYP1A2
SCHEMBL29381501 0.87 KMT2A (0.63) SMN1; SMN2KMT2AMAPTHTTCYP1A2
SCHEMBL17204101 0.79 MAPT (0.61) SMN1; SMN2KMT2AMAPTHTTCYP1A2
SCHEMBL12110309 0.79 KMT2A (0.62) SMN1; SMN2KMT2AMAPTHTTCYP1A2
SCHEMBL3287154 0.79 MAPT (0.61) SMN1; SMN2KMT2AMAPTHTTCYP1A2
SCHEMBL13412132 0.77 PIK3CA (0.58) SMN1; SMN2MAPTHTTHPGDRAB9A
SCHEMBL9003193 0.77 KMT2A (0.76) SMN1; SMN2KMT2AMAPTHTTCYP1A2
SCHEMBL7509466 0.76 CRHBP (0.66) SMN1; SMN2KMT2AMAPTHTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
EP-3299367-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2018-03-28 — — EP disclosed
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2017-09-14 — — US disclosed
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2017-09-14 — — US disclosed
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2017-09-14 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
US-9242969-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
US-9242969-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
US-9242969-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
EP-2970216-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2016-01-20 — — EP disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS SMN1; SMN2 3547/4885KMT2A 756/4885MAPT 1965/4885
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS SMN1; SMN2 3547/4885KMT2A 756/4885MAPT 1965/4885
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS SMN1; SMN2 3547/4885KMT2A 756/4885MAPT 1965/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS SMN1; SMN2 3547/4885KMT2A 756/4885MAPT 1965/4885
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS SMN1; SMN2 3547/4885KMT2A 756/4885MAPT 1965/4885
US-10245267-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS SMN1; SMN2 3547/4885KMT2A 756/4885MAPT 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.